Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and PrecigenZacks Investment Research • 08/27/26
Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to BuyZacks Investment Research • 08/20/26
Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor UpdatesSeeking Alpha • 08/20/26
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?The Motley Fool • 08/10/26
Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?Zacks Investment Research • 08/07/26
Iovance: Stock Soars On Q2 Earnings - Critical Data In Melanoma, NSCLC Due SeptemberSeeking Alpha • 08/06/26
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/06/26
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate UpdatesGlobeNewsWire • 08/06/26
Will Iovance Biotherapeutics (IOVA) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/30/26
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026GlobeNewsWire • 07/30/26
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 07/04/26
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 06/23/26
Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in AustraliaGlobeNewsWire • 06/03/26
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?The Motley Fool • 06/02/26